ClinicalTrials.gov
ClinicalTrials.gov Menu

An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01623479
Recruitment Status : Completed
First Posted : June 20, 2012
Results First Posted : September 19, 2012
Last Update Posted : September 19, 2012
Sponsor:
Information provided by (Responsible Party):
Allergan

Brief Summary:
This is an observational study of patients treated with bimatoprost 0.03% (Latisse®) for at least 12 months for hypotrichosis of the eyelashes.

Condition or disease Intervention/treatment
Eyelash Hypotrichosis Drug: bimatoprost 0.03%

Study Type : Observational
Actual Enrollment : 585 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Study Start Date : November 2010
Actual Primary Completion Date : September 2011
Actual Study Completion Date : September 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hair Loss
Drug Information available for: Bimatoprost

Group/Cohort Intervention/treatment
Hypotrichosis of the Eyelashes
Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
Drug: bimatoprost 0.03%
Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
Other Name: Latisse®




Primary Outcome Measures :
  1. Percentage of Subjects Satisfied With Latisse® [ Time Frame: Day 1 ]
    Overall subject satisfaction with Latisse® was assessed on a 5-point scale (Very Satisfied, Satisfied, Neutral, Unsatisfied, and Very Unsatisfied). The percentage of subjects satisfied and very satisfied is reported.


Secondary Outcome Measures :
  1. Number of Applications of Latisse® Per Week [ Time Frame: Day 1 ]
    Number of applications of Latisse® per week as reported by the subjects.

  2. Percentage of Subjects Satisfied Wtih Their Eyelashes [ Time Frame: Day 1 ]
    Overall subject satisfaction with their eyelashes was assessed on a 5-point scale (Very Satisfied, Satisfied, Neutral, Unsatisfied, and Very Unsatisfied). The percentage of subjects satisfied and very satisfied is reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects with hypotrichosis of the eyelashes
Criteria

Inclusion Criteria:

  • Hypotrichosis of the eyelashes
  • Using bimatoprost ophthalmic solution 0.03% (Latisse®) for at least 12 months

Exclusion Criteria:

  • Use of any over-the-counter medication(s) for eyelash growth

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01623479


Locations
United States, California
Santa Ana, California, United States
Sponsors and Collaborators
Allergan
Investigators
Study Director: Medical Director Allergan

Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT01623479     History of Changes
Other Study ID Numbers: GMA-LTS-10-001
CED2009 ( Other Identifier: Allergan )
First Posted: June 20, 2012    Key Record Dates
Results First Posted: September 19, 2012
Last Update Posted: September 19, 2012
Last Verified: August 2012

Additional relevant MeSH terms:
Hypotrichosis
Hair Diseases
Skin Diseases
Bimatoprost
Antihypertensive Agents